Japanese generics giant Sawai is pulling out of the US market, agreeing a deal to divest its Upsher-Smith business to Taiwan’s Bora Pharmaceuticals in a deal worth a little over $200m. As Sawai explained its rationale for the move, Bora pointed to “significant opportunities” for its TWi commercial prescription unit arising from the acquisition.

Japanese generics giant Sawai is pulling out of the US market, agreeing a deal to divest its Upsher-Smith business to Taiwan’s Bora Pharmaceuticals in a deal worth a little over $200m. As Sawai explained its rationale for the move, Bora pointed to “significant opportunities” for its TWi commercial prescription unit arising from the acquisition.

US FDA makes five changes to ease burden of risk management program for acne drug – going further than the agency initially seemed comfortable with in March, though not always in line with what the generic sponsors were seeking.

Plus deals involving Sanofi/Adocia, Sirnaomics/EDIRNA, Eisai/DRI Healthcare, Sangamo/Voyager, Liquidia/Pharmosa, Tonix/Upsher-Smith and more.